SECTION 4.2.14 510(K) SUMMARY

MAR 2 6 2003

PREDICATE DEVICE	New DEVICE
Diagnostic Ultrasound BladderScan™	Diagnostic Ultrasound BladderMass TM
BVI 6100 Ultrasound System	BVM 6500 Ultrasound System
Predicate: The BladderScan [™] BVI 6100 is intended to project ultrasound energy through the lower abdomen of the nonpregnant patient to obtain an image of the bladder and uses that image to calculate the bladder volume noninvasively. The BladderScan BVI 6100 is contraindicated for fetal use and for use on pregnant patients.	New device: The BladderMass TM BVM 6500 is intended to project ultrasound energy through the lower abdomen of the nonpregnant patient to obtain an image of the bladder and uses that image to calculate the bladder volume and bladder wall mass noninvasively. The BladderMass BVM 6500 is contraindicated for fetal use and for use on pregnant patients.

510(k) Summary (As required by 21 CFR 807.92(a))

A.	Submitter Information	Compay: Diagnostic Ultrasound 21222 30 th Drive SE, Suite 120 Bothell, WA 98041 Phone: 425-867-1348 ext.1667 Fax: 425-883-2896 Email: ngertlar@dxu.com Contact: Nancy J. Gertlar, RAC Director, Regulatory Affairs Date: March 5, 2003
В.	Device Information Trade/Proprietary Name:	Diagnostic Ultrasound BladderMass BVM™ 6500 Ultrasound System
	Common Name:	Diagnostic Ultrasound System with Accessories
	Classification Name:	Regulatory Class: II Review Category: Tier II Classification Panel: Radiology Ultrasonic Pulsed Echo Imaging System • FR Classification 892.1560 • Product Code 90-IYO Diagnostic Ultrasound Transducer • FR Classification 892.1570 • Product Code 90-ITX
	Predicate Device:	Diagnostic Ultrasound BladderScan BVI 6100 Ultrasound System, K022153
	Device Description:	The Diagnostic Ultrasound BladderMass BVM TM 6500 Ultrasound System is a hand-held, battery powered, software controlled ultrasound system used to acquire and display real time B-mode images of the bladder. The system is intended to non invasively monitor bladder volume on an intermittent basis. The system is an offective, low cost, simple option for use in a clinical hospital or

06/05/2003

	Intended Use:	system is an effective, low cost, simple option for use in a clinical hospital or nursing home setting or for home use under medical supervision. New device: The BladderMass TM BVM 6500 is
		intended to project ultrasound energy through the lower abdomen of the nonpregnant patient to obtain an image of the bladder and uses that image to calculate the bladder volume and bladder wall mass noninvasively. The BladderMass 6500 is contraindicated for fetal use and for use on pregnant patients.
C.	Comparison of Required Technological Characteristics:	The Diagnostic Ultrasound System and its integrated 3.7 MHz mechanical sector transducer operate only in B-mode to locate and automatically measure bladder volume. Bladder volume, patient gender, non optimal directional aiming, battery status, and usage rate indicators are all displayed on the Diagnostic Ultrasound BladderMass BVM TM 6500 Ultrasound System scanner. The ultrasonic power transmitted the system is not user adjustable. The hand-held Diagnostic Ultrasound BladderMass BVM TM 6500 Ultrasound System is applied to the patient's abdomen with a single patient use Sontac® hydrogel pad, manufactured by Diagnostic Ultrasound to optimize the performance of the Diagnostic Ultrasound BladderMass BVM TM 6500 Ultrasound System. The transducer collects cross- sectional images of the bladder from twenty four (24) scan planes. From this information, the Diagnostic Ultrasound System constructs a finite element model of the bladder and automatically computes the volume of urine via volumetric integration and the bladder wall mass.
		In order to demonstrate the BladderMass accuracy claimed in 0270-1238-xx-55, a third party vendor was contracted to build tissue

equivalent phantoms with known dimensions. The suppliers, Computerized Imaging Reference Systems (CIRS) is known for supplying medical imaging phantoms to the medical marketplace.

The BladderMass Phantom is essentially a balloon which gets filled with urine mimicking material and then the filled balloon is surrounded with tissue mimicking material. Both the tissue and urine mimicking material have been used by CIRS for many years in bladder volume phantoms. The balloon is injected molded to have a thickness of approximately 3mm when relaxed, due to the precision of the injection molded process this thickness does not vary by more than +/- 0.25 mm across the surface of the balloon.

Different urine volumes and thus different bladder wall thickness measurements can be made by filling the balloon with different amounts of urine mimicking material. Since the same mold is used for both balloons, the balloon mass will be relatively constant between phantoms while the bladder wall thickness and urine volume can change significantly.

During the manufacturing process, CIRS measures key parameters of the physical parts as the parts are constructed. These measurements are all NIST traceable and each phantom comes with a certification sheet listing the measurements.

These results obtained through the Diagnostic Ultrasound BladderMass BVMTM 6500 Ultrasound System are compared to the expected results derived from the NIST traceable measurements. In addition to these measurements, additional measurements are taken by standard ultrasound systems, such as the Sonosite 180, to compare bladder mass measurements.

The traditional method of measuring bladder mass is to use a standard ultrasound system,

		make random bladder wall measurements, and calculate the expected bladder wall mass. The Diagnostic Ultrasound BladderMass BVM TM 6500 Ultrasound System takes measurements of the bladder wall and calculates the bladder wall mass. Accuracy has been demonstrated by comparing CIRS measurements to the measurements of the Diagnostic Ultrasound BladderMass BVM TM 6500 Ultrasound System. A Calibration Targeting System, consisting of a heli-coil shaped calibration target along with a specially designed container, allows the user to easily scan a known geometrically shaped target. Data may be optically transmitted to a remote location when connected to the clinician's personal computer via a communication cradle. Connection to this communication cradle allows for battery charging, remote calibration, usage monitoring, software updates, and data transfer through a web-based interface, referenced as "ScanPoint TM ". The Diagnostic Ultrasound BladderMass BVM TM 6500 Ultrasound System also includes a universal charger cradle for the non replaceable lithium ion battery incorporated into the hand held instrument.
D.	Summary and Conclusion of Non Clinical and Clinical Testing	All clinical and non clinical testing of the Diagnostic Ultrasound BladderMass BVM TM 6500 Ultrasound System indicate that the Diagnostic Ultrasound BladderMass BVM TM 6500 Ultrasound System is substantially equivalent to the Diagnostic Ultrasound BladderScan TM BVI 6100 Ultrasound System, and all acoustic measurements remain within Preamendment limits.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 2 6 2003

Diagnostic Ultrasound Corporation % Mr. Heinz Joerg Steneberg Responsible Third Party TUV Rheinland of North America 12 Commerce Road NEWTOWN CT 06470 Re: K030763

Trade/Device Name: Diagnostic Ultrasound

BladderMass BVM 6500

Regulation Number: 21 CFR 892.1560 Regulation Name: Ultrasonic pulsed echo

imaging system

Regulation Number: 21 CFR 892.1570

Regulation Name: Diagnostic ultrasonic trensducer

Regulatory Class: II

Product Code: 90 IYO and ITX

Dated: March 7, 2003 Received: March 11, 2003

Dear Mr.Steneberg:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Mancy C. Brogdon
Nancy C. Brogdon

Director, Division of Reproductive, Abdominal and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

DIAGNOSTIC ULTRASOUND INDICATIONS FOR USE FORM System: BladderMassTM BVM 6500 Ultrasound System

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human

body as follows:

Clinical Application		Mode of Operation							
General	Specific	В	La contraction of the contractio						
(Track I	(Tracks I & III)					Doppler	(Spec.)	(Spec.)	
only)	,					• •			
Ophthalmic	Ophthalmic								
	Fetal		·						
	Abdominal	P							
	Intra-operative								
	(Abdominal organs and	:							
	vascular)								
	Intra-operative (Neuro.)								
Fetal	Laparoscopic								
Imaging									
& Other	Pediatric								
	Small Organ (breast,								
	thyroid, testicles)								
	Neonatal Cephalic								
	Adult Cephalic								
	Trans-rectal			,					
	Trans-vaginal								
	Trans-urethral								
	Trans-esoph. (non-Card.)								
	Musculo-skel.								
	(Convent.)								
	Musculo-skel.								
	(Superfic.)								
	Intra-luminal								
	Other (spec.)								
	Cardiac Adult								
Cardiac	Cardiac Pediatric								
	Trans-esophageal (card.)								
	Other (spec.)								
Peripheral	Peripheral vessel								
Vessel	Other (spec.)								

N= new indication; P= previously cleared by FDA (K022153)

Prescription Use (Per 21 CFR 801.109)	David a.	Segmon	
(Division	n Sign-Off) n of Reproductive, A	Abdominal,	
and Rad		K030763	000045